Literature DB >> 139317

Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate.

R W Horton, G M Anlezark, M C Sawaya, B S Meldrum.   

Abstract

The time course of changes in behaviour, seizure response and cerebral monoamine and gamma-aminobutyric acid (GABA) metabolism has been studied in relation to the anticonvulsant actions of di-n-propylacetic acid (DPA) and ethanolamine-O-sulphate (EOS) on sound-induced seizures in DBA/2 mice. Changes in cerebral monoamine metabolism after EOS (75 or 150 mug, intracerebroventricularly) were not related to its anticonvulsant action. The primary effect was GABA-transaminase inhibition (by 50-70%) leading to a 2-4 fold increase in cerebral GABA concentration. Increases in brain GABA concentration (maximally 36%), 5-hydroxyindoleacetic acid (5HIAA, maximally 134%) and homovanillic acid (HVA, maximally 183%) were seen after DPA (400-600 mg/kg, i.p.). The time course of the increases in HVA and 5HIAA did not correlate with the anticonvulsant effect. Elimination of these increases by the use of inhibitors of monoamine synthesis (alpha-methyl-p-tyrosine and p-chlorophenyl-alanine) did not alter the anticonvulsant effect of DPA. Experiments using probenecid suggested that the increases in 5HIAA and HVA after DPA result from inhibition of their active transport out of the brain.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 139317     DOI: 10.1016/0014-2999(77)90259-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Anaesthesia abolishes the effect of valproate on extracellular 5-HIAA, DOPAC and ascorbate as measured in rat striatum by differential pulse voltammetry.

Authors:  F Crespi; P E Keane; M Morre
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

2.  Effects of some anticonvulsant drugs on brain GABA level and GAD and GABA-T activities.

Authors:  L Battistin; M Varotto; G Berlese; G Roman
Journal:  Neurochem Res       Date:  1984-02       Impact factor: 3.996

3.  Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system.

Authors:  A Quatraro; G Consoli; A Stante; A Minei; A Ceriello; N Passariello; D Giugliano
Journal:  Acta Diabetol Lat       Date:  1986 Jan-Mar

4.  Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, gamma-acetylenic GABA (4-amino-hex-5-ynoic acid) and gamma-vinyl GABA (4-amino-hex-5-enoic acid).

Authors:  B Meldrum; R Horton
Journal:  Psychopharmacology (Berl)       Date:  1978-09-15       Impact factor: 4.530

5.  Effect of sodium valproate on motor function regulated by the activation of GABA receptors.

Authors:  A Kuruvilla; N J Uretsky
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 6.  Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.

Authors:  W Löscher
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

Review 7.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Acute effects of sodium valproate and gamma-vinyl GABA on regional amino acid metabolism in the rat brain: incorporation of 2-[14C]glucose into amino acids.

Authors:  A G Chapman; K Riley; M C Evans; B S Meldrum
Journal:  Neurochem Res       Date:  1982-09       Impact factor: 3.996

9.  Valproate enhances GABA-A mediated inhibition of locus coeruleus neurones in vitro.

Authors:  H R Olpe; M W Steinmann; M F Pozza; F Brugger; M Schmutz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

10.  A comparative study of the pharmacology of inhibitors of GABA-metabolism.

Authors:  W Löscher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.